Drug Profile
RSD 1000
Alternative Names: RSD1000Latest Information Update: 01 Jun 2020
Price :
$50
*
At a glance
- Originator Cardiome Pharma; Rhythm Search Developments
- Developer Cardiome Pharma; Nonindustrial source; Rhythm Search Developments
- Class Antiarrhythmics; Small molecules
- Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 27 May 2020 Correvio Pharma has been acquired by ADVANZ PHARMA
- 15 May 2018 Cardiome Pharma is now called Correvio Pharma
- 27 Mar 2003 Discontinued - Preclinical for Arrhythmias in Canada (unspecified route)